Ophthalmology (Eye)

Subahari Raviskanthan; Melissa M. Chu; Peter W. Mortensen; Andrew G. Lee; Nagham Al-Zubidi

doi:10.1007/978-3-031-00241-0_11

Ophthalmology (Eye)

Subahari Raviskanthan, Melissa M. Chu, Peter W. Mortensen, Andrew G. Lee, Nagham Al-Zubidi

Head & Neck Surgery

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Ophthalmic immune-related adverse events occur at a lower frequency than other immune-related adverse events, in part due to the immune privilege of the eye. Their severity can range from mild and not requiring specific treatment to severe, requiring discontinuation of the medication as well as management with systemic immunosuppressive medications. The spectrum of events can involve all structures of the eyes, with keratoconjunctivitis sicca and uveitis being the two most common ocular manifestations. This chapter will review the epidemiology, clinical presentations, evaluation, management, and prognosis for patients with ophthalmic adverse events of immune checkpoint inhibition.

Original language	English (US)
Title of host publication	Managing Immunotherapy Related Organ Toxicities
Subtitle of host publication	A Practical Guide
Publisher	Springer International Publishing
Pages	231-253
Number of pages	23
ISBN (Electronic)	9783031002410
ISBN (Print)	9783031002403
DOIs	https://doi.org/10.1007/978-3-031-00241-0_11
State	Published - Jan 1 2022

Keywords

Conjunctivitis
Episcleritis
Giant cell arteritis
Keratitis
Myasthenia gravis
Ophthalmic
Optic neuropathy
Orbital inflammation
Retinal detachment
Scleritis
Thyroid eye disease
Uveitis
Vasculitis

ASJC Scopus subject areas

General Medicine
General Immunology and Microbiology

Access to Document

10.1007/978-3-031-00241-0_11

Cite this

@inbook{26ad6a54050643e4ae47ce054ae6d9f7,

title = "Ophthalmology (Eye)",

abstract = "Ophthalmic immune-related adverse events occur at a lower frequency than other immune-related adverse events, in part due to the immune privilege of the eye. Their severity can range from mild and not requiring specific treatment to severe, requiring discontinuation of the medication as well as management with systemic immunosuppressive medications. The spectrum of events can involve all structures of the eyes, with keratoconjunctivitis sicca and uveitis being the two most common ocular manifestations. This chapter will review the epidemiology, clinical presentations, evaluation, management, and prognosis for patients with ophthalmic adverse events of immune checkpoint inhibition.",

keywords = "Conjunctivitis, Episcleritis, Giant cell arteritis, Keratitis, Myasthenia gravis, Ophthalmic, Optic neuropathy, Orbital inflammation, Retinal detachment, Scleritis, Thyroid eye disease, Uveitis, Vasculitis",

author = "Subahari Raviskanthan and Chu, {Melissa M.} and Mortensen, {Peter W.} and Lee, {Andrew G.} and Nagham Al-Zubidi",

note = "Publisher Copyright: {\textcopyright} The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2022",

year = "2022",

month = jan,

day = "1",

doi = "10.1007/978-3-031-00241-0_11",

language = "English (US)",

isbn = "9783031002403",

pages = "231--253",

booktitle = "Managing Immunotherapy Related Organ Toxicities",

publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Ophthalmology (Eye)

AU - Raviskanthan, Subahari

AU - Chu, Melissa M.

AU - Mortensen, Peter W.

AU - Lee, Andrew G.

AU - Al-Zubidi, Nagham

N1 - Publisher Copyright: © The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2022

PY - 2022/1/1

Y1 - 2022/1/1

N2 - Ophthalmic immune-related adverse events occur at a lower frequency than other immune-related adverse events, in part due to the immune privilege of the eye. Their severity can range from mild and not requiring specific treatment to severe, requiring discontinuation of the medication as well as management with systemic immunosuppressive medications. The spectrum of events can involve all structures of the eyes, with keratoconjunctivitis sicca and uveitis being the two most common ocular manifestations. This chapter will review the epidemiology, clinical presentations, evaluation, management, and prognosis for patients with ophthalmic adverse events of immune checkpoint inhibition.

AB - Ophthalmic immune-related adverse events occur at a lower frequency than other immune-related adverse events, in part due to the immune privilege of the eye. Their severity can range from mild and not requiring specific treatment to severe, requiring discontinuation of the medication as well as management with systemic immunosuppressive medications. The spectrum of events can involve all structures of the eyes, with keratoconjunctivitis sicca and uveitis being the two most common ocular manifestations. This chapter will review the epidemiology, clinical presentations, evaluation, management, and prognosis for patients with ophthalmic adverse events of immune checkpoint inhibition.

KW - Conjunctivitis

KW - Episcleritis

KW - Giant cell arteritis

KW - Keratitis

KW - Myasthenia gravis

KW - Ophthalmic

KW - Optic neuropathy

KW - Orbital inflammation

KW - Retinal detachment

KW - Scleritis

KW - Thyroid eye disease

KW - Uveitis

KW - Vasculitis

UR - http://www.scopus.com/inward/record.url?scp=85163442147&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85163442147&partnerID=8YFLogxK

U2 - 10.1007/978-3-031-00241-0_11

DO - 10.1007/978-3-031-00241-0_11

M3 - Chapter

AN - SCOPUS:85163442147

SN - 9783031002403

SP - 231

EP - 253

BT - Managing Immunotherapy Related Organ Toxicities

PB - Springer International Publishing

ER -

Ophthalmology (Eye)

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this